![]() |
![]() |
![]() |
![]() |
||
|
|||||
GAP-107B8 was developed employing proprietary computer models PharmaGap researchers have developed for select PKC isoforms. PharmaGap’s computer modeling abilities are a core competency and form the basis for the Company’s intellectual property and pipeline of drug compounds targeting PKC for the treatment of cancer and other diseases. PharmaGap is pursuing a strategy to partner its lead drug candidates at the pre-clinical or early clinical trial stage. The Company recognizes that its strengths rest in drug design and “proof of principle” validation and that larger pharmaceutical/biotech partners have the resources necessary to move the Company’s compounds into human clinical use. PharmaGap is a spin-out from Canada’s premier biological research organization, the National Research Council of Canada. Offices and labs are located in Ottawa, Ontario, Canada.
|
Recent News 02.01.10 12.29.09 12.02.09 10.21.09 |
||||